Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Regulation of AmpC-Driven β-Lactam Resistance in Pseudomonas aeruginosa: Different Pathways, Different Signaling.

Torrens G, Hernández SB, Ayala JA, Moya B, Juan C, Cava F, Oliver A.

mSystems. 2019 Dec 3;4(6). pii: e00524-19. doi: 10.1128/mSystems.00524-19.

2.

Comparative Analysis of Peptidoglycans From Pseudomonas aeruginosa Isolates Recovered From Chronic and Acute Infections.

Torrens G, Escobar-Salom M, Pol-Pol E, Camps-Munar C, Cabot G, López-Causapé C, Rojo-Molinero E, Oliver A, Juan C.

Front Microbiol. 2019 Aug 27;10:1868. doi: 10.3389/fmicb.2019.01868. eCollection 2019.

3.

Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant Acinetobacter baumannii.

Vázquez-Ucha JC, Martínez-Guitián M, Maneiro M, Conde-Pérez K, Álvarez-Fraga L, Torrens G, Oliver A, Buynak JD, Bonomo RA, Bou G, González-Bello C, Poza M, Beceiro A.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e01092-19. doi: 10.1128/AAC.01092-19. Print 2019 Oct.

PMID:
31383666
4.

In Vivo Validation of Peptidoglycan Recycling as a Target to Disable AmpC-Mediated Resistance and Reduce Virulence Enhancing the Cell-Wall-Targeting Immunity.

Torrens G, Sánchez-Diener I, Jordana-Lluch E, Barceló IM, Zamorano L, Juan C, Oliver A.

J Infect Dis. 2019 Oct 22;220(11):1729-1737. doi: 10.1093/infdis/jiz377.

PMID:
31325363
5.

Profiling the susceptibility of Pseudomonas aeruginosa strains from acute and chronic infections to cell-wall-targeting immune proteins.

Torrens G, Barceló IM, Pérez-Gallego M, Escobar-Salom M, Tur-Gracia S, Munar-Bestard M, González-Nicolau MDM, Cabrera-Venegas YJ, Rigo-Rumbos EN, Cabot G, López-Causapé C, Rojo-Molinero E, Oliver A, Juan C.

Sci Rep. 2019 Mar 5;9(1):3575. doi: 10.1038/s41598-019-40440-w.

6.

The importance of dark adaptation for forensic examinations; an evaluation of the Crime-lite Eye™.

McMurchie B, King RSP, Kelly PF, Torrens GE.

Sci Justice. 2019 Mar;59(2):138-144. doi: 10.1016/j.scijus.2018.10.006. Epub 2018 Oct 24.

PMID:
30798860
7.

In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae.

Moya B, Barcelo IM, Cabot G, Torrens G, Palwe S, Joshi P, Umarkar K, Takalkar S, Periasamy H, Bhagwat S, Patel M, Bou G, Oliver A.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00128-19. doi: 10.1128/AAC.00128-19. Print 2019 May.

8.

Interplay between Peptidoglycan Biology and Virulence in Gram-Negative Pathogens.

Juan C, Torrens G, Barceló IM, Oliver A.

Microbiol Mol Biol Rev. 2018 Sep 12;82(4). pii: e00033-18. doi: 10.1128/MMBR.00033-18. Print 2018 Dec. Review.

9.

Diversity and regulation of intrinsic β-lactamases from non-fermenting and other Gram-negative opportunistic pathogens.

Juan C, Torrens G, González-Nicolau M, Oliver A.

FEMS Microbiol Rev. 2017 Nov 1;41(6):781-815. doi: 10.1093/femsre/fux043. Review.

PMID:
29029112
10.

Synthesis and Antimicrobial Studies of New Antibacterial Azo-Compounds Active against Staphylococcus aureus and Listeria monocytogenes.

Piotto S, Concilio S, Sessa L, Diana R, Torrens G, Juan C, Caruso U, Iannelli P.

Molecules. 2017 Aug 19;22(8). pii: E1372. doi: 10.3390/molecules22081372.

11.

Targeting the permeability barrier and peptidoglycan recycling pathways to disarm Pseudomonas aeruginosa against the innate immune system.

Torrens G, Pérez-Gallego M, Moya B, Munar-Bestard M, Zamorano L, Cabot G, Blázquez J, Ayala JA, Oliver A, Juan C.

PLoS One. 2017 Jul 25;12(7):e0181932. doi: 10.1371/journal.pone.0181932. eCollection 2017.

12.

The order and priority of research and design method application within an assistive technology new product development process: a summative content analysis of 20 case studies.

Torrens GE.

Disabil Rehabil Assist Technol. 2018 Jan;13(1):66-77. doi: 10.1080/17483107.2017.1280547. Epub 2017 Mar 12. Review.

PMID:
28286994
13.

Impact of AmpC Derepression on Fitness and Virulence: the Mechanism or the Pathway?

Pérez-Gallego M, Torrens G, Castillo-Vera J, Moya B, Zamorano L, Cabot G, Hultenby K, Albertí S, Mellroth P, Henriques-Normark B, Normark S, Oliver A, Juan C.

MBio. 2016 Oct 25;7(5). pii: e01783-16. doi: 10.1128/mBio.01783-16.

14.

Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms.

Torrens G, Cabot G, Ocampo-Sosa AA, Conejo MC, Zamorano L, Navarro F, Pascual Á, Martínez-Martínez L, Oliver A.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6407-10. doi: 10.1128/AAC.01282-16. Print 2016 Oct.

15.
16.

Hand performance assessment of ten people with rheumatoid arthritis when using a range of specified saucepans.

Torrens GE, Hann J, Webley M, Joy J, Sutherland IA.

Disabil Rehabil. 2000 Feb 15;22(3):123-34.

PMID:
10749034
17.

The development of the Port-a-Bidet: a portable bidet for people with minimal hand function.

Burkitt J, Martin G, Kay GH, Torrens GE, Chapman C, Sandbach D.

Med Eng Phys. 1996 Sep;18(6):515-8.

PMID:
8843407

Supplemental Content

Loading ...
Support Center